H-1B Filings
13
Major sponsor. DOL labor condition applications on file.
Invagen Pharmaceuticals, INC. in NY (Manufacturing) is a sponsorship-and-safety profile: 13 H-1B LCAs plus an employer-specific OSHA injury record, with no WARN notices in this corpus.
Invagen Pharmaceuticals, INC. (NY): · 13 H-1B LCAs at a $110,000 disclosed median · OSHA Grade C (DART 1.33)
According to DOL OFLC H-1B disclosures, OSHA ITA injury logs, and state WARN Act notices, Invagen Pharmaceuticals, INC. in NY carries 13 H-1B wage filings on record, a $110,000 median wage (below the $124,488 national median), a middling C OSHA safety grade and no WARN layoff notices on file. Every figure is a federal filing, not an estimate; see methodology for coverage limits.
The record at a glance
Compared with the rest of PlainEmployers' federal employer corpus, H-1B filing volume ranks #3,940 of 51,370 sponsors in this corpus (about the 92nd percentile), and disclosed median wage sits at the 37th percentile of 272,125 credible H-1B wage rows.
Figures above come from DOL H-1B LCAs and this employer's OSHA injury log; no WARN notices are on file here.
A weighted composite of DOL H-1B sponsorship and pay, OSHA establishment injury records, and WARN Act layoff notices, not culture, benefits, or "is this a good place to work." Missing tracks drop out and their weight redistributes so sparse records are not silently deflated.
Weights (redistributed when a track is N/A): Sponsorship scale (H-1B volume) 15% · Disclosed pay (H-1B wage percentile) 25% · Workplace safety (OSHA DART percentile) 35% · Layoff stability (WARN percentile) 25%. Sources: DOL OFLC · OSHA ITA · state WARN filings.
DOL LCA release change
H-1B Filings
13
Major sponsor. DOL labor condition applications on file.
Median H-1B Salary
$110,000
Below national median. Across 13 disclosed positions
OSHA Safety Grade
Grade C · DART 1.33
Riskier than industry average. vs 1.14 same 2-digit NAICS sector (OSHA ITA 2022–2023, hours-weighted)
Where Invagen Pharmaceuticals, INC.'s H-1B wage sits nationally
Median disclosed wage vs. all US employers with H-1B filings
$110,000 Top 63% higher than 37% of 272,125 US employers
Each bar is a $20K-wide band; taller bars hold more US employers. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source DOL Office of Foreign Labor Certification, H-1B Disclosure Data · August 2026
Filing-count-weighted median across this employer's own disclosed H-1B positions (+21.1% year over year), not a company-wide raise, and not adjusted for role mix changes between years.
| Field | Value | Source |
|---|---|---|
| Employer Name | Invagen Pharmaceuticals, INC. | DOL OFLC / OSHA |
| Industry | Manufacturing | NAICS / DOL |
| State | NY | U.S. Federal Records |
| H-1B Filings | 13 | DOL OFLC LCA Disclosure |
| H-1B Median Salary | $110,000 | DOL OFLC LCA Disclosure |
| OSHA Safety Grade | C | OSHA ITA |
| OSHA DART Rate | 1.33 | OSHA ITA Establishment Records |
| Tracks not on file | WARN notices | Empty by design, not estimated |
Invagen Pharmaceuticals, INC.'s values above reflect the most recent DOL Labor Condition Applications, OSHA Injury Tracking Application records on file for this employer in NY (Manufacturing). In this corpus, H-1B filing volume ranks #3,940 of 51,370 sponsors in this corpus (about the 92nd percentile); disclosed median wage sits at the 37th percentile of 272,125 credible H-1B wage rows; OSHA DART rate is safer than roughly 48% of 214,554 employers with an establishment injury record.
| Job Title | Median |
|---|---|
| Sr. R&D Project Manager | $148,000 |
| Sr. Manager – Planning & Integration | $143,000 |
| Senior Manager, Analytical R&D | $142,908 |
| Section Head Quality Control | $126,000 |
| Associate Director, Quality Assurance | $119,704 |
| QC Supervisor and EHS Coordinator | $113,306 |
| IT Business Partner | $110,000 |
| QA-Supervisor | $97,669 |
| QC CHEMIST-III | $93,000 |
| Production Planner | $91,452 |
| Pilot Plant QC Chemist III | $90,000 |
| Pilot Plant QC Chemist I | $70,000 |
| QC Chemist I | $68,000 |
Invagen Pharmaceuticals, INC.'s most extreme placement is sponsorship scale: 13 H-1B LCAs rank higher than 92% of sponsors in this corpus (#3,940 of 51,370).
FY2025 added 3 filings versus FY2024 (60%), a sponsorship expansion visible in the raw LCA counts.
Disclosed medians moved from $96,200 (FY2024) to $116,505 (FY2025) (+21.1%), weighted by this employer's own LCA rows — not a company-wide raise and not role-mix adjusted.
No WARN Act mass-layoff notices are on file for Invagen Pharmaceuticals, INC. among Manufacturing employers we track.
A $110,000 disclosed median lands near the middle of the wage distribution (37th percentile vs $124,488 nationally).
DART 1.3 tracks close to the 1.1 sector average (Grade C).
Invagen Pharmaceuticals, INC.'s DART rate (days away/restricted/transferred per 100 FTE) vs the hours-weighted 2-digit NAICS sector average from OSHA ITA 2022–2023 (Manufacturing).
Total reported injuries on file: 23.
Where Invagen Pharmaceuticals, INC. sits
Across the 201 Manufacturing sponsors in this corpus with both an H-1B filing count and a credible disclosed-wage median, Invagen Pharmaceuticals, INC. files more petitions than 0% of them and discloses a higher median wage than 8%, the selective, below-median pay quadrant. Filing volume is hiring scale, not pay; the axes are independent DOL OFLC disclosures (13 filings · $110,000 median here).
Each muted dot is one manufacturing peer from a filings-stratified sample of 42; the brand marker is Invagen Pharmaceuticals, INC.. Source: DOL Office of Foreign Labor Certification H-1B LCA disclosures (credible wages recomputed from per-position filings, excluding parse errors above $500k).
Invagen Pharmaceuticals, INC.'s nearest H-1B-filing peers in Manufacturing (home state NY). Each card links to that employer's federal-records profile.
Two federal-records peer sets for Invagen Pharmaceuticals, INC., both outside NY so the neighborhoods are not the same-industry VsCard above.
Nearest injury-rate peers outside NY (DART 1.33 here).
Peers are nearest-neighbor matches on disclosed filing counts and OSHA ITA DART rates; employers with fewer than 100 H-1B filings or fewer than 10 reported injuries are excluded from the comparison corpus.
What to check before working with Invagen Pharmaceuticals, INC.
For Invagen Pharmaceuticals, INC., read sponsorship pay (13 H-1B LCAs, median $110,000) next to the OSHA safety grade (C).
Invagen Pharmaceuticals, INC.'s figures are legally filed public records (DOL, OSHA, state WARN), not reviews or vendor estimates; a missing row is not proof the underlying activity never happened.
Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from OSHA and the DOL Wage and Hour Division. Consult a qualified professional before making decisions based on this data.
Among 272,125 credible H-1B wage rows in this corpus, Invagen Pharmaceuticals, INC.'s disclosed median of $110,000 sits at the 37th percentile (below the $124,488 national median). The chart above uses a COUNT-exact percentile (rows below this wage ÷ total), not an interpolated estimate.
Invagen Pharmaceuticals, INC. has 13 H-1B filings on record, ranking #3,940 of 51,370 sponsors in this corpus (about the 92nd percentile by volume). Filing volume is a sponsorship signal, not a headcount or hiring-quality score.
Invagen Pharmaceuticals, INC. carries Grade C from its establishment injury record (23 injuries on file; DART 1.33). That DART rate is safer than roughly 48% of 214,554 employers with an injury record in this corpus. Grades compare DART against industry averages, see the Interpreting Safety Grades guide.
Related guides: How OSHA safety grades are calculated · Using H-1B wage filings in salary negotiation
Read our methodology - how this data is sourced, computed, and verified.
This profile is rendered directly from DOL H-1B disclosure filings and OSHA Injury Tracking Application records, no number is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of August 2026.